Vizamyl is a radioactive diagnostic agent indicated for PET imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment.

Vizamyl is the only beta-amyloid PET tracer FDA-approved for color image interpretation across all three planes and all five brain regions.

PiB Legacy: Vizamyl builds on the heritage of the original Pittsburgh Compound B (PiB) PET radiotracer.
Standardization: It enables normalized and standardized reads through a semi-quantitative PONS anchor point.
Interpretation Requirement: Uptake in any one of the five regions, including the striatum, supports a positive scan interpretation.
Support: GE HealthCare provides comprehensive claims support including prior authorization, billing, peer-to-peer preparation, and more.

Please see full Prescribing Information HERE

Save the date to attend our Read with the expert: Amyloid PET imaging with Vizamyl (flutemetamol F 18 injection) for typical and challenging patient cases

June 23, 2025 | 05:30 pm - 06:30 pm CT, New Orleans Convention Center 2nd Floor RM 06-07

Nearly 7 million Americans are living with Alzheimer’s disease. As the aging population grows and new therapies enter the market, amyloid PET imaging is an increasingly important tool for early and accurate diagnosis. GE HealthCare is pleased to provide an opportunity to learn more from Dr. Phillip Kuo about how Vizamyl’s advanced capabilities can support you in both typical and challenging patient cases.

Upon completion of this session, you will be prepared to:
• Interpret a Vizamyl PET image
• Review a range of clinical case studies
• Complete the Vizamyl reader training program assessment